FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics

Apr 27, 2020

|

NEW YORK – Personal Genome Diagnostics said on Monday that it has received US Food and Drug Administration clearance for its PGDx Elio Tissue Complete, a next-generation sequencing diagnostic assay that molecular labs can use to perform genomic profiling of cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics

To read the full story....

Breaking News

AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials

Takeda Scores First-Line FDA Approval for Alunbrig in ALK-Positive Metastatic Lung Cancer

Invivoscribe Receives Supplemental Approval for AML Kit

Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

Genentech's Tecentriq Receives First-Line FDA Approval for High PD-L1-Expressing Lung Cancer

Featured White Papers

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

What's Popular?

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing

AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials

Invivoscribe Receives Supplemental Approval for AML Kit

Sponsorships